PROS1 and prostate carcinoma: The current diagnosis of prostate cancer using PSA testing, digital rectal examination (DRE) and histopathological biopsy has specificity and patient compliancy limitations, both of which can be developed and evaluated apparent deficits in the diagnosis of prostate cancer (2, 3).